Medical Needs in the Treatment of Psychotic Disorders
- 2.8k Downloads
Schizophrenia and psychotic disorders represent psychiatric disease patterns characterized by remarkable impairment arising from alterations in cognition, perception, and mood. Although these severe illnesses have been known for more than 100 years, psychopharmacological treatment of their characteristically broad spectrum of symptoms as well as patients’ quality of life, compliance, and time to relapse still remain a challenge in everyday clinical practice. In the following, we will provide a brief synopsis of first-generation antipsychotics (FGAs) followed by a detailed description of current second-generation antipsychotics (SGAs) along with their effects and side effects to evaluate unmet needs in the treatment of schizophrenia and psychotic disorders.
Overall, drug profiles differ concerning their efficacy, associated side effects, cost, and mechanism of action. Thus, a shared decision-making process taking all these factors into account is necessary to develop an effective treatment based on currently approved compounds. To date, however, the spectrum of options is limited and only serves a limited proportion of patients. In addition, certain symptoms do not respond well to currently available strategies or respond only at the price of considerable side effects leading to reduced compliance and adherence in a substantial number of cases.
Unmet needs in the field of antipsychotic treatment are found in a wide range of areas starting from efficacy, safety and tolerability, compliance and adherence, and continuing to stage-dependent and more personalized approaches.
KeywordsMedical needs First- and second-generation antipsychotics Schizophrenia Compliance Patient adherence Quality of life Side effects
We gratefully acknowledge the helpful discussion and input from Dr. A. Meyer-Lindenberg during the preparation of this manuscript. We would like to thank Ms. W. VanSyckel for carefully editing this article.
- Adams CE, Awad G, Rathbone J, Thornley B (2007) Chlorpromazine versus placebo for schizophrenia Cochrane Database Syst Rev (2):CD000284Google Scholar
- Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S (2010) Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (11):CD006633Google Scholar
- Burlon M (2007) Pharmakotherapy der Schizophrenie—“State of the art”. NeuroTransmitter 5:59–70Google Scholar
- Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS, Anderson W, Dhansay MA, Phillips A, Shurin S, Walport M, Ewart W, Savill SJ, Bordin IA, Costello EJ, Durkin M, Fairburn C, Glass RI, Hall W, Huang Y, Hyman SE, Jamison K, Kaaya S, Kapur S, Kleinman A, Ogunniyi A, Otero-Ojeda A, Poo MM, Ravindranath V, Sahakian BJ, Saxena S, Singer PA, Stein DJ (2011) Grand challenges in global mental health. Nature 475:27–30PubMedCrossRefGoogle Scholar
- Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999) Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20:491–505CrossRefGoogle Scholar
- Essali A, Al-Haj Haasan N, Li C, Rathbone J (2009) Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev (1):CD000059Google Scholar
- Gross G, Drescher K (2012) The role of dopamine D3 receptors in antipsychotic activity and cognitive functions. In: Geyer M, Gross G (eds) Novel antischizophrenia treatments, vol 213, Handbook of Experimental Pharmacology. Springer, HeidelbergGoogle Scholar
- Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganev K, Heiden W, Holmberg SK, Janca A, Lee PW, Leon CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D (2001) Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 178:506–517PubMedCrossRefGoogle Scholar
- Heal DJ, Gosden J, Jackson HC, Cheetham SC, Smith SL (2012) Metabolic consequences of antipsychotic therapy – preclinical and clinical perspectives on diabetes, diabetic ketoacidosis and obesity. In: Gross G, Geyer MA (eds) Current antipsychotics, vol 212, Handbook of Experimental Pharmacology. Springer, HeidelbergGoogle Scholar
- Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163:185–194PubMedCrossRefGoogle Scholar
- Hiemke C, Pfuhlmann B (2012) Interactions and monitoring of antipsychotic drugs. In: Gross G, Geyer MA (eds) Current antipsychotics, vol 212, Handbook of Experimental Pharmacology. Springer, HeidelbergGoogle Scholar
- Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006) Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63:1079–1087PubMedCrossRefGoogle Scholar
- Joy CB, Adams CE, Lawrie SM (2006) Halopridol versus placebo for schizophrenia. Cochrane Database Syst Rev 18(4):CD003082Google Scholar
- Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Grobbee DE (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085–1097PubMedCrossRefGoogle Scholar
- Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HG, Kissling W, Leucht S (2009) Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev: (4) CD006569Google Scholar
- Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S (2010a) Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (3):CD006654Google Scholar
- Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, Srisurapanont M, Kissling W, Leucht S (2010b) Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (1):CD006625Google Scholar
- Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35:51–68PubMedCrossRefGoogle Scholar
- McDonagh M, Peterson K, Carson S, Fu R, Thakurta S (2010) Drug class review: atypical antipsychotic drugs: Final Update 3 Report [Internet] Drug Class Reviews, Portland (OR)Google Scholar
- McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600–610PubMedCrossRefGoogle Scholar
- Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S (2003) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60:82–91PubMedCrossRefGoogle Scholar
- Naber D, Riedel M, Klimke A, Vorbach EU, Lambert M, Kuhn KU, Bender S, Bandelow B, Lemmer W, Moritz S, Dittmann RW (2005) Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 111:106–115PubMedCrossRefGoogle Scholar
- Robinson DG, Woerner MG, Napolitano B, Patel RC, Sevy SM, Gunduz-Bruce H, Soto-Perello JM, Mendelowitz A, Khadivi A, Miller R, McCormack J, Lorell BS, Lesser ML, Schooler NR, Kane JM (2006) Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry 163:2096–2102PubMedCrossRefGoogle Scholar
- Srisurapanont M, Maneeton B, Maneeton N (2004) Quetiapine for schizophrenia. Cochrane Database Syst Rev (2):CD000967Google Scholar
- Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK (2006) Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163:611–622PubMedCrossRefGoogle Scholar